Scinai Immunotherapeutics doubles CDMO revenue, but can the Recipharm deal change the bigger picture?
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.
How Piramal Pharma Solutions’ Morpeth tablet press upgrade sharpens its play in potent oral solid manufacturing
Piramal Pharma Solutions has added new high-containment tablet capacity at Morpeth. Read what this could change for CDMO competition and potent drug supply.
LGM Pharma’s $15m U.S. manufacturing expansion signals a deeper shift away from import dependence in pharma supply chains
LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.
Lonza sells capsules and health ingredients unit to Lone Star Funds, retains 40% stake
Lone Star Funds acquires Lonza’s CHI division in a carve-out reshaping pharma capsule supply. Read what this means for the CDMO market.
How Kenox Pharmaceuticals is targeting the OINDP CDMO gap with integrated clinical manufacturing
Kenox Pharmaceuticals announces clinical manufacturing readiness for inhaled and nasal drug products. What this means for OINDP development timelines and IVBE strategy.
Why GSK’s expanded Bora Pharmaceuticals partnership reflects new CDMO selection logic
Explore what the Bora Pharmaceuticals and GSK manufacturing deal reveals about long-term supply strategy and CDMO market shifts. Read the full analysis.
BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape
Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.
What Rakuten Medical’s deal with LOTTE Biologics signals for photoimmunotherapy scale-up
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
Why Kashiv BioSciences’ Gujarat plant expansion could redefine biomanufacturing in India
Kashiv BioSciences raises INR 648 crore to expand its Gujarat biologics facility. Find out what this means for India’s role in global drug manufacturing.
What sterile drug manufacturers should expect from AST and Marchesini in 2026
AST, a United States-based provider of aseptic fill-finish systems for pharmaceutical and biotech manufacturers, has entered a strategic partnership with Italy’s Marchesini Group, a global leader in pharmaceutical packaging machinery. Under the agreement announced on December 10, 2025, Marchesini Group has acquired a 44.39 percent equity stake in AST. The deal aims to combine AST’s […]